Vice President, Clinical Development
- Employer
- 4D Molecular Therapeutics
- Location
- Remote, United States
- Posted date
- Sep 28, 2026
View more categories
- Discipline
- Clinical, Clinical Development, Clinical Research
- Required Education
- Doctorate/PHD/MD
- Position Type
- Full time
By clicking apply, your email address will be shared with the employer.
Job Details
Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. The 4DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4DMT in the future.
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery
GENERAL SUMMARY
Reporting to the Chief Medical Officer, the VP Clinical Development, Ophthalmology provides strategic and operational leadership for the global development of ophthalmic genetic medicines in Drug Development.
We seek an experienced physician to play a critical role at 4DMT as we spearhead the introduction of intravitreally delivered genetic medicines for the treatment of the most common causes of irreversible blindness. The VP, Clinical Development will be a primary point person for medical oversight of clinical studies, with responsibilities including medical monitoring, review and interpretation of clinical trial data, clinical trial design, protocol development, and drafting of key clinical documents such as protocols, CSRs, briefing packages, INDs, NDAs, BLAs, MAAs, and other regulatory documents. This role will be responsible for timely execution of deliverables in close collaboration with relevant internal and external partners.
RESPONSIBILITIES:
Serve as the primary medical monitor for multiple ophthalmology clinical trials, providing expert oversight of patient safety, data integrity, and protocol adherence throughout study execution.
Direct and mentor a team of medical monitors, ensuring high standards of medical oversight and data review, while maintaining accountability for real-time monitoring activities and timely delivery of critical clinical trial outputs.
Provide medical leadership for cross-functional internal workstreams including pharmacovigilance, biostatistics, clinical operations, regulatory affairs, etc.
Provide oversight and lead teams responsible for development plans, study protocols, amendments, ICFs, IBs, INDs, annual reports, CSRs, regulatory response documents, and other regulatory submissions or documents as appropriate.
Collaborate closely with Clinical Operations and be accountable for clinical trial conduct and timelines for associated key deliverables.
Keep up to date with compliance, SOPs and adhere to ICH, GCP, and relevant regulatory guidelines.
Provide medical leadership for internal audits and regulatory inspections.
Assist in preparation of materials for Advisory Board meetings, BOD meetings, etc
Represent 4DMT and lead interactions and collaborations with potential partners.
Represent the Ophthalmology Therapeutic Area with key external stakeholders, including patients and patient advocacy groups, external experts, investors, and the ophthalmic and biotech business communities
Travel domestically and internationally as required, approximately 20%. Other duties as assigned; nothing in this job description restricts management’s right to assign or reassign duties and responsibilities to this job at any time.
QUALIFICATIONS:
Education:
MD Degree
Clinical training in Ophthalmology preferred
Retina fellowship training a plus
Board Certification (or equivalent) preferred
Experience:
Minimum of 8 years of biopharma industry experience in drug development.
Phase 3 ophthalmology experience; retinal disease highly preferred.
Experience with NDA, BLA or MAA submission(s). Drug approval(s) a plus.
Experience with gene therapy, other areas of Drug Development and commercialization is a plus.
Skills:
Strong interpersonal skills and high emotional coefficient
Highly effective written and verbal communication skills
Excellent analytical, problem-solving and strategic planning skills.
Up to date understanding of the ophthalmic competitive landscape with a focus on retina
Prior clinical trial experience in retina highly preferred.
Ability to understand and translate complex data to key messages
Ability to thrive in a fast-paced environment.
Proven ability to prioritize effectively
Proven ability to plan and conduct clinical trials ensuring high-quality trial execution and results within established timelines; demonstrated track record working effectively in cross-functional teams and workstreams including pharmacovigilance, biostatistics, clinical operations, and regulatory affairs.
Experience in successfully presenting and interacting with the Ophthalmic Retina Community and regulatory authorities in US, EU and APAC
Integrated understanding of FDA, EMA, ICH, and GCP guidelines. Prior interactions with FDA and EMA regulatory agencies is desirable.
Track record of thinking strategically and executing to strategy
Demonstrated success in influencing colleagues and senior leaders in various departments.
Experience building and leading teams and driving engagement in a matrixed environment.
Attention to detail, internal drive to generate high-quality work, and sense of passion and urgency to achieve team and program goals.
Track record of developing talent
Demonstrates high integrity.
Physical Requirements and Working Conditions:
Physical Activity - Repetitive motions: Making substantial movements (motions) of the wrists, hands, and/or fingers. Fingering: Picking, pinching, typing or otherwise working, primarily with fingers rather than with whole hand or arm as in handling. Talking: Expressing or exchanging ideas by means of the spoken word.
Physical Requirements - Sedentary work: Exerting up to 10 pounds of force occasionally and/or a negligible amount of force frequently or constantly to lift, carry, push, pull or otherwise move objects, including the human body. Sedentary work involves sitting most of the time. Jobs are sedentary if walking and standing are required only occasionally and all other sedentary criteria are met.
Working Conditions - The worker is not substantially exposed to adverse environmental conditions (as in typical office or administrative work).
Base salary compensation range: $350,000 - $430,000
Please note, the base salary compensation range and actual salary offered to the final candidate depends on various factors: candidate’s geographical location, relevant work experience, skills, and years of experience.
4DMT provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, national origin, age, disability, genetic information, marital status, status as a covered veteran, and any other category protected under applicable federal, state, provincial and local laws.
Equal Opportunity Employer/Protected Veterans/Individuals with Disabilities
Company
4DMT is a gene therapy company with a transformative discovery platform --Therapeutic Vector Evolution --that enables our “disease first” approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the underlying disease.
At 4DMT we are creating and developing optimized “biopharmaceutical grade” AAV vectors that will allow us uniquely to unlock the full potential of gene therapy. Our customized and proprietary AAV vectors are each designed, according to a 4DMT Target Vector Profile, to deliver genes to specific cells and tissues in the body to eradicate both rare and large market diseases.
While AAV gene therapy pioneers are making great strides with the first wave of products, hurdles still exist with the use of conventional vectors. The most commonly used AAV capsids (e.g., AAV2, 5, 8 and 9) were identified either 1) as contaminants in lab stocks of adenovirus, or 2) through monkey tissue processing. Therefore, these conventional vectors are not targeted specifically to any tissue in the body. This can lead to inefficient and non-specific delivery, thus requiring extremely high doses and potentially resulting in toxicities (including inflammation), high manufacturing burdens and suboptimal efficacy. In addition, suboptimal routes of delivery can be required for delivery to the right tissues (e.g., subretinal delivery to the retina). Finally, pre-existing neutralizing antibodies in many patients can limit efficacy, clinical trial enrollment and market sizes. 4DMT Innovation empowers us to create new and improved next generation AAV capsids to allow targeted delivery of our products by the optimal clinical route of administration.
At 4DMT we use our robust discovery platform, termed “Therapeutic Vector Evolution,” to create customized and proprietary gene delivery vehicles (novel AAV vectors) to deliver genes to specific tissues and cells in the body by the optimal route of administration. We use the power of evolution to create and refine these optimized vectors through genetic diversification and then natural selection in vivo.
4D Purpose Statement: Boldly Innovating to Unlock the Full Potential of Gene Therapy for Countless Patients
GUIDING PRINCIPLES
Dare to Cure - Patients are waiting. Create big dreams for patients and take calculated risks to achieve them
Break Boundaries - Question the status quo and innovate beyond conventional approaches
Beyond Yourself - It's about patients, their families, our team, our families. We strengthen each other.
Prepare and Execute Relentlessly - Start with the end in mind, over-prepare and make contingency plans to your contingency plans
We invite all of you who share our passion and vision in creating the ultimate gene therapy products to cure genetic and rare diseases in children and adults. We seek the best people in the industry who identify with our mission and innovative results-driven approach. We offer an inspiring and collaborative environment that encourages individual contributions, recognizes performance in multiple ways, offers generous benefits and provides challenging opportunities for career development.
- Phone
- 510-505-2680
- Location
- 5858 Horton St. Suite 455
Emeryville
California
94608